Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of testing for breast cancer susceptibility genes.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 1 Jan 2000

Holland Margaret L, Huston Alissa, Noyes Katia

Abstract excerpt

OBJECTIVES: Genetic mutations in breast cancer susceptibility genes BRCA1/2 are associated with an increased risk of breast/ovarian cancers. Cost-effective preventive measures are available for women who test positive. The objective of this study was to determine at what risk of mutation it is cost-effective to test women for BRCA1/2 mutations. METHODS: A semi-Markov model accrued costs and quality-adjusted life...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Health Care Costs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Life Expectancy

Share to Mastectomy

Share to Models, Economic

Share to Ovariectomy

Share to Patient Satisfaction

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 18647256
DOI: 10.1111/j.1524-4733.2008.00418.x

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of testing for breast cancer susceptibility genes.PMID 18647256Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.Semantic proximity Read ↗

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.Semantic proximity Read ↗

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.Semantic proximity Read ↗

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer PreventionSemantic proximity Read ↗

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.Semantic proximity Read ↗

Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income CountrySemantic proximity Read ↗

A discrete event simulation to evaluate the cost effectiveness of germline <i>BRCA1</i> and <i>BRCA2</i> testing in UK women with ovarian cancerSemantic proximity Read ↗

Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.Semantic proximity Read ↗

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.Semantic proximity Read ↗

Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.Semantic proximity Read ↗

Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.